Siemens Presents New Artis Q and Artis Q.zen Product Lines for Angiography

Chicago, November 25, 2012 – At the 98th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), from November 25 to 30 in Chicago, Siemens Healthcare (Booth #831, East Building/Lakeside Center at McCormick Place, Hall D) will display for the first time its revolutionary new X-ray tube and detector technology for its Artis Q and Artis Q.zen angiography systems – which Siemens has designed to improve minimally invasive therapy of diseases such as coronary artery disease, stroke, and cancer. The new X-ray tube in both the Artis Q and Artis Q.zen series is intended to help physicians identify small vessels up to 70 percent better than conventional X-ray tube technology. The Artis Q.zen combines this innovative X-ray source with a new detector technology designed to support interventional imaging in ultra-low-dose ranges to patients, doctors and medical staff – particularly during longer interventions. With these new developments, Siemens Healthcare again demonstrates its innovative strength and market competitiveness – two key components of its Agenda 2013 two-year global Sector initiative.

Two hardware components are crucial for angiographic image quality: the X-ray tube and the detector. X-rays emitted by the tube pass through the patient and hit the detector, which converts them to image signals.

The second generation of Siemens’ flat emitter technology is key to the advances made in the X-ray tube for the Artis Q and Artis Q.zen product lines. Instead of the coiled filaments used in conventional X-ray tubes, flat emitter technology is used exclusively in the new tube to emit electrons. Flat emitters are designed to enable smaller quadratic focal spots that lead to improved visibility of small vessels by up to 70 percent. Both physicians and patients benefit from a high level of detail in imaging-supported interventional therapy. Neurologists can more precisely measure blood circulation in specific areas of the brain, for example, while stenoses in the heart’s smallest blood vessels can be spotted in coronary angiography.

Examinations using ultra-low-dose radiation
The Artis Q.zen series has been designed to combine the X-ray tube with a detector technology that allows detection at ultra-low radiation levels. Artis Q.zen imaging can use doses as low as half the standard levels applied in angiography. This improvement is the result of several innovations, including a fundamental change in detector technology. Until now, almost all detectors have been based on amorphous silicon. The new crystalline silicon structure of the Artis Q.zen detector is designed to be more homogenous, allowing for more effective amplification of the signal, greatly reducing the electronic noise even at ultra-low doses.

The Artis Q.zen was developed to support better imaging quality at ultra-low-dose ranges, reducing the radiation exposure of patients, physicians, and medical staff. This is especially important in dose-sensitive application fields such as pediatric cardiology and radiology, or electrophysiology, which is being used more frequently as rates of cardiac arrhythmia increase in an aging population.

Innovative applications for interventional imaging
In addition to these hardware innovations are several software applications designed to improve interventional imaging. In coronary artery disease treatment, the applications allow precise correlation of angiography images with ultrasound images taken by a probe inside the coronary arteries. Stents are imaged in real time during therapy, with motion stabilization created by simultaneous correction for the heartbeat.

Other new 3D applications are designed to image the smallest structures inside the head. Their high spatial resolution is crucial for imaging intracranial stents or other miniscule structures such as the cochlea in the inner ear. Moving organs such as the lungs can be imaged in 3D in less than 3 seconds, reducing motion artifacts and the required amount of contrast agent. Through visualization and measurement of blood volumes in the liver or other organs, Siemens’ functional 3D imaging provides a basis for planning therapies such as chemo-embolization of hepatic tumors.

The Artis Q and Artis Q.zen are pending 510(k) clearance and are not yet commercially available in the United States.

Launched by Siemens Healthcare Sector in November 2011, Agenda 2013 is a two-year global initiative to further strengthen the Healthcare Sector's innovative power and competitiveness. Specific measures will be implemented in four fields of action: Innovation, Competitiveness, Regional Footprint, and People Development.

The Siemens Healthcare Sector is one of the world's largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, medical information technology and hearing aids. Siemens offers its customers products and solutions for the entire range of patient care from a single source – from prevention and early detection to diagnosis, and on to treatment and aftercare. By optimizing clinical workflows for the most common diseases, Siemens also makes healthcare faster, better and more cost-effective. Siemens Healthcare employs some 51,000 employees worldwide and operates around the world. In fiscal year 2012 (to September 30), the Sector posted revenue of 13.6 billion euros and profit of 1.8 billion euros. For further information please visit: www.siemens.com/healthcare.